ID
45234
Beschrijving
Principal Investigator: Dawood Darbar, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Atrial Fibrillation https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000439 The goal of this study was to identify genetic predictors of response to rate control therapy in patients with AF. We conducted a genome-wide association study (GWAS) focusing on subjects with a history of atrial fibrillation. Rate control therapy for AF uses a range of drugs (beta-adrenergic receptor blockers, calcium channel blockers, and digitalis) to depress conduction through the AV node, thereby preventing rapid rates and minimizing symptoms. In large groups of patients, such as the Vanderbilt AF Registry (a clinical and genetic repository with over 1200 patients with ECG-confirmed AF) from which these study subjects were drawn, approximately 5% display failure of aggressive AV nodal-blocking therapy to control ventricular rate. In these patients, interruption of the AV node by ablation and pacemaker implantation are necessary for adequate rate control. Study cases were individuals who underwent AV node ablation and pacemaker implantation after combined therapy with 3 AV nodal-blocking agents was ineffective in rate control. Controls for this study were individuals who met standardized rate-control efficacy criteria (as described in AFFIRM study, Wyse et al, NEJM 2002; PMID: 12466506) for optimal rate control with 2 or fewer AV nodal-blocking agents. Two additional groups were genotyped by RIKEN: An additional group of patients with AF as well as subjects undergoing cardiac surgery in whom AF did not occur post-operatively. All study participants were recruited and treated/evaluated at Vanderbilt University Medical Center. This study was conducted by the Pharmacogenomics of Arrhythmia Therapy subgroup of the Pharmacogenetics Research Network, a nationwide collaboration of scientists studying the genetic contributions to drug response variability. Genotyping was performed by the RIKEN research institute in Japan using the Illumina 610 Quad Beadchip platform.
Link
Trefwoorden
Versies (2)
- 21-07-22 21-07-22 - Simon Heim
- 12-10-22 12-10-22 - Adrian Schulz
Houder van rechten
Dawood Darbar, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA
Geüploaded op
12 oktober 2022
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000439 PGRN-RIKEN: Rate Control Therapy in Patients with Atrial Fibrillation
Subject ID, consent group, and affection status of participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- Sample ID, subject ID, and sample use variables obtained from participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- Subject ID, gender, age, race, history of hypertension, diabetes mellitus, congestive heart failure, and myocardial infarction, type of atrial fibrillation among participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
Similar models
Subject ID, consent group, and affection status of participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, consent group, and affection status of participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- Sample ID, subject ID, and sample use variables obtained from participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.
- Subject ID, gender, age, race, history of hypertension, diabetes mellitus, congestive heart failure, and myocardial infarction, type of atrial fibrillation among participants with or without atrial fibrillation and involved in the "A Genome-Wide Association Comparative Analysis of Eesponse of AF Patients to Rate Control Therapy; A Collaboration between the NIH Pharmacogenomics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine" project.